Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018:39:13-17.
doi: 10.1007/8904_2017_41. Epub 2017 Jul 7.

The Prevalence of PMM2-CDG in Estonia Based on Population Carrier Frequencies and Diagnosed Patients

Mari-Anne Vals  1   2   3 , Sander Pajusalu  4   5 , Mart Kals  6 , Reedik Mägi  6 , Katrin Õunap  4   5
Affiliations

The Prevalence of PMM2-CDG in Estonia Based on Population Carrier Frequencies and Diagnosed Patients

Mari-Anne Vals et al. JIMD Rep. 2018.

Abstract

PMM2-CDG (MIM#212065) is the most common type of congenital disorders of glycosylation (CDG) caused by mutations in PMM2 (MIM#601785). In Estonia, five patients from three families have been diagnosed with PMM2-CDG. Our aim was to evaluate the presence of different PMM2-CDG-causing mutations in a population-based cohort and to calculate the expected frequency of PMM2-CDG in Estonia. Also, we analyzed the prevalence of PMM2-CDG based on our patient group data. To calculate the expected frequency of PMM2-CDG, we used the whole genome sequencing data of 2,244 participants from biobank of the Estonian Genome Center, University of Tartu. Nineteen individuals carried mutated PMM2 alleles and altogether, five different mutations were identified. The observed carrier frequency for all PMM2 disease-causing mutations was thus 1/118, and for the most frequent mutation p.R141H, 1/224. The expected frequency of the disease in Estonian population is 1/77,000. It is comparable to the current prevalence of PMM2-CDG for the less than 18 years age group, which is 1/79,000. In conclusion, the frequency of PMM2-CDG in Estonia is lower than in other European populations reported thus far. We demonstrate that biobank data can be useful for gaining new information about the epidemiology of the PMM2-CDG.

Keywords: Biobank; Carrier frequency; N-glycosylation; PMM2-CDG; p.R141H.

PubMed Disclaimer

References

    1. Bjursell C, Erlandson A, Nordling M, et al. PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat. 2000;16:395–400. doi: 10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.0.CO;2-T. - DOI - PubMed
    1. Kjaergaard S, Skovby F, Schwartz M. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur J Hum Genet. 1998;6:331–336. doi: 10.1038/sj.ejhg.5200194. - DOI - PubMed
    1. Leitsalu L, Haller T, Esko T, et al. Cohort profile: Estonian biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol. 2015;44:1137–1147. doi: 10.1093/ije/dyt268. - DOI - PubMed
    1. Martinsson T, Bjursell C, Stibler H, et al. Linkage of a locus for carbohydrate-deficient glycoprotein syndrome type I (CDG1) to chromosome 16p, and linkage disequilibrium to microsatellite marker D16S406. Hum Mol Genet. 1994;3:2037–2042. - PubMed
    1. Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet. 1998;62:542–550. doi: 10.1086/301763. - DOI - PMC - PubMed

LinkOut - more resources